Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001017007 | SCV001178027 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-09-19 | criteria provided, single submitter | clinical testing | The p.T3387I variant (also known as c.10160C>T), located in coding exon 26 of the BRCA2 gene, results from a C to T substitution at nucleotide position 10160. The threonine at codon 3387 is replaced by isoleucine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526795 | SCV005039635 | uncertain significance | not specified | 2024-03-20 | criteria provided, single submitter | clinical testing |